| Date Filed | Type | Description |
| 09/29/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 09/29/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/16/2023 |
4
| Doshi Dipal (President and CEO) has filed a Form 4 on Entrada Therapeutics, Inc.|
Txns:
| Sold 1,000 shares
@ $15.6713, valued at
$15.7k
|
|
| 08/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/10/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Entrada Therapeutics Appoints Gina Chapman to its Board of Directors BOSTON, Aug. 10, 2023 -- Entrada Therapeutics, Inc. , a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle -therapeutics as a new class of medicines, today announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023. Ms. Chapman currently serves as President and Chief Executive Officer of CARGO Therapeutics. “Gina is a seasoned leader with more than thirty years of experience driving the commercial and operational growth of numerous biopharmaceutical companies,” said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics. “With a proven track record of advancing therapeutics into the market, Gin..." |
|
| 08/08/2023 |
10-Q/A
| Quarterly Report for the period ended March 31, 2023 [amend] |
| 08/08/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/04/2023 |
4
| KREHER NERISSA (Chief Medical Officer) has filed a Form 4 on Entrada Therapeutics, Inc.|
Txns:
| Sold 9,280 shares
@ $15.0876, valued at
$140k
Sold 1,000 shares
@ $16.0117, valued at
$16k
Sold 68 shares
@ $16.82, valued at
$1.1k
Sold 9,464 shares
@ $14.7432, valued at
$139.5k
Sold 6,898 shares
@ $14.1376, valued at
$97.5k
Exercised 10,348 options to buy
@ $2.1, valued at
$21.7k
Exercised 9,464 options to buy
@ $2.1, valued at
$19.9k
Exercised 6,898 options to buy
@ $2.1, valued at
$14.5k
|
|
| 08/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/01/2023 |
8-K
| Quarterly results |
| 07/12/2023 |
4
| WENTWORTH KORY JAMES (CFO) has filed a Form 4 on Entrada Therapeutics, Inc.|
Txns:
| Sold 6,116 shares
@ $17.9788, valued at
$110k
Sold 3,884 shares
@ $17.9979, valued at
$69.9k
Exercised 6,116 options to buy
@ $2.1, valued at
$12.8k
Exercised 3,884 options to buy
@ $2.1, valued at
$8.2k
|
|
| 07/12/2023 |
4
| Dowden Nathan J (COO) has filed a Form 4 on Entrada Therapeutics, Inc.|
Txns:
| Sold 3,200 shares
@ $18.0016, valued at
$57.6k
Sold 3,897 shares
@ $18.048, valued at
$70.3k
|
|
| 07/12/2023 |
4
| Sethuraman Natarajan (Chief Scientific Officer) has filed a Form 4 on Entrada Therapeutics, Inc.|
Txns:
| Sold 3,026 shares
@ $18.002, valued at
$54.5k
Sold 14,852 shares
@ $18.039, valued at
$267.9k
|
|
| 07/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/10/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/30/2023 |
4
| WENTWORTH KORY JAMES (CFO) has filed a Form 4 on Entrada Therapeutics, Inc.|
Txns:
| Exercised 8,790 options to buy
@ $2.1, valued at
$18.5k
|
|
| 06/12/2023 |
4
| PARMAR KUSH (10% Owner) has filed a Form 4 on Entrada Therapeutics, Inc.|
Txns:
| Granted 16,000 options to buy
@ $14.67, valued at
$234.7k
|
|
| 06/12/2023 |
4
| Thistle Mary (Director) has filed a Form 4 on Entrada Therapeutics, Inc.|
Txns:
| Granted 16,000 options to buy
@ $14.67, valued at
$234.7k
|
|
| 06/12/2023 |
4
| Crowley John F (Director) has filed a Form 4 on Entrada Therapeutics, Inc.|
Txns:
| Granted 16,000 options to buy
@ $14.67, valued at
$234.7k
|
|
| 06/12/2023 |
4
| KIM PETER S (Director) has filed a Form 4 on Entrada Therapeutics, Inc.|
Txns:
| Granted 16,000 options to buy
@ $14.67, valued at
$234.7k
|
|
| 06/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/27/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/25/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/25/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/25/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/19/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 04/19/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
|